Contineum Therapeutics, Inc. Logo

Contineum Therapeutics, Inc.

Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.

CTNM | US

Overview

Corporate Details

ISIN(s):
US21217B1008
LEI:
Country:
United States of America
Address:
3565 GENERAL ATOMICS COURT, SUITE 200, 92121 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel, oral small molecule therapies. The company focuses on pioneering treatments for conditions at the intersection of neuroscience, inflammation, and immunology (NI&I). Its pipeline is based on clinically validated biological targets and includes a potential best-in-class LPA1R antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS), and a potential first-in-class M1R antagonist for major depressive disorder (MDD) in collaboration with a Johnson & Johnson company. Formerly Pipeline Therapeutics, Contineum aims to develop impactful treatments for serious neurological, inflammatory, and fibrotic diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Contineum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Contineum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Contineum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden KARO
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America KPTI
KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America KZIA
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940

Talk to a Data Expert

Have a question? We'll get back to you promptly.